| Literature DB >> 18656257 |
F Menasria1, A G B Azebaze, C Billard, A M Faussat, A E Nkengfack, M Meyer, J P Kolb.
Abstract
A series of 10 heterocyclic compounds purified from Allanblackia were tested on two B cell lines, ESKOL and EHEB, and on cells from B-CLL patients. Several molecules inhibited the proliferation of both cell lines and promoted apoptosis of B-CLL cells through different mechanisms, some of them elicited a dissipation of the mitochondrial transmembrane potential, other triggered caspase-3 activation and cleavage of the inducible nitric oxide synthase. Blood mononuclear cells and B-lymphocytes from healthy donors appeared less sensitive than B-CLL cells. These results indicate that these molecules may be of interest in the development of new therapies for B-CLL.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18656257 DOI： 10.1016/j.leukres.2008.05.017
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156